Anoikis-related gene signatures can aid prognosis of lung adenocarcinoma

Background.Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, and while advancements in diagnosis, surgery, radiotherapy, and molecular therapy have improved clinical prognosis, the long-term survival rate and quality of life of patients remain unsatisfactory.Therefore, identifying new prognostic biomarkers and potential therapeutic targets is crucial.Objectives.This study aimed to analyze the role of anoikis-related gene characteristics in LUAD. Materials and methods.The anoikis-related genes were obtained from the GeneCards database.Genetic expression data and clinical characteristic information were collected from The Cancer Genome Atlas (TCGA)-LUAD, and the Gene Expression Omnibus (GEO) GSE31210, GSE37745, and GSE68465 datasets.Random survival forest and least absolute shrinkage and selection operator (LASSO) models were applied to construct the risk model.An analysis of immune cell infiltration and function was performed with the scores.Results.Four prognosis-related genes (TLE1, GLI2, PLK1, and BAK1) were obtained and used to construct the anoikis score.We found that the patient survival rate was higher in the low-anoikis score (LAS) group.Moreover, both the stromal and immune scores were negatively correlated with the anoikis score.With the increase of the anoikis score, the levels of natural killer cells, regulatory T cells, CD4 + T cells, CD8 + T cells, B cells, and macrophages decreased.The anoikis score had a negative regulatory relationship with the immune response, natural killer cell activation and T cell activation.The TP53 mutation was significant in LUAD patients and was present in 56% of the high-anoikis score (HAS) group and in 40% of the LAS group. Conclusions.The anoikis score was associated with poor prognosis in LUAD patients.Anoikis-related genes were associated with tumor immune dysregulation and TP53 mutation in LUAD.This study opens a new perspective for LUAD therapy.